Anlon Healthcare Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1cbshv97hsj3th96j5gjpyq1.pdf

Key Takeaways


Margin Compression: The Raw Material Shock

Punit Rasadia: "When you are going to buy the raw materials, you have to pay the as per the current market price. But while you are maintaining the relation with your customers, because we are dealing in the B2B business, so you hardly have 10 to 15 customers. So, you cannot go to your customer every day and ask them to change the prices depend on the prices of crude. At certain level you have to maintain your credibility also, so if your margin is getting affected then also, we have to supply."

Revenue Composition & Seasonality

Punit Rasadia: "In pharma or chemical, it is not right measurement to measure the quarter-on-quarter basis. Better I suggest that you'll compare with the H1 or H2 basis."

Strategic Expansion: Subsidiaries, Capacity & New Businesses


CDMO, Product Pipeline & R&D


Working Capital & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin recoveryNormalize to 25–30% rangeBy H1 FY27 (Q2–Q3)
FY27 consolidated revenue₹350–400 croreFY27 full year
FY28 consolidated revenue~₹700 crore, contingent on Anlon expansion completing on scheduleFY28 full year
Apiqo and Bizotic become 100% subsidiariesShare swap process completedBy end of Q2 FY27
Anlon site capacity expansion commissioned~₹130 crore CAPEX, ~1,200 MT addedBy Q1 FY28, if everything goes well, subject to statutory approvals
Remember India commercial operations beginRevenue generation startsQ4 FY27
CDMO molecule 1 commercial supplyFirst commercial supplyQ3 FY27
CDMO molecules 2 and 3 commercial supplyCommercial supplyQ4 FY27 or Q1 FY28
Pain management ointment launchDCGI approval and first-time-in-India launchWithin one year
Anlon Biologics revenue generationFirst revenueFY28 Q4
Anlon Medicare revenue generationFirst revenueQ2 FY28
Positive operating cash flowSome lower but positive operating cash flowBefore end of FY27
Seven new DMF filingsAcross additional therapeutic categoriesWithin FY27
FY27 standalone Anlon revenue~₹180 croreFY27 full year
FY27 PAT margin12–13%, described as conservative due to potential statutory approval delaysFY27 full year

Key Metrics

MetricQ1 FY27
Consolidated total income₹87.62 cr, vs ₹33.31 cr in Q1 FY26
Consolidated EBITDA₹15.65 cr, vs ₹6.26 cr in Q1 FY26
Consolidated PAT₹8.28 cr, vs ₹3.55 cr in Q1 FY26
EBITDA margin~17%, down from prior year; raw material price surge and Remember India consolidation weighed on margins
FY27 revenue guidance₹350–400 cr, reiterated; Q1 at ₹87 cr, H2 expected heavier than H1
FY27 EBITDA margin guidance25–27%, expected to normalize by Q3 FY27 as price revisions flow through; Q2 expected better than Q1
FY27 PAT margin guidance12–13%, on a conservative basis; FY28 also expected 12–13% on a conservative basis
FY28 revenue expectation~₹700 cr, contingent on Anlon site expansion commissioning by Q1 FY28
Installed manufacturing capacity1,400–1,600 metric tonnes per annum, post-acquisitions
Capacity utilization62.37%, on a consolidated basis; Anlon standalone at peak level, but can be increased at Apiqo and Bizotic
Anlon site expansion CAPEX~₹130 cr, funded via ~₹70 cr debt at 8.5–8.6% interest and internal accruals
Revenue mix – Apiqo~₹45 cr in Q1; FY27 expected ₹120–150 cr
Revenue mix – Anlon standalone~₹32 cr in Q1; FY27 expected ~₹180 cr
Revenue mix – Bizotic~₹12 cr in Q1; FY27 expected ~₹60 cr
Remember India Health links stake63.98% acquired, transaction completed 8 May 2026; revenue contribution not expected until Q4 FY27 or FY28
Fine chemical and specialty chemical contribution₹120–150 cr expected in FY27
Trade receivable days170–180 days; payment terms 90 days, actual collection 130–135 days; management noted industry norm is 150–160 days
Gross margin target40–45%
Target revenue CAGR~30% over the next three years